This page contains a Flash digital edition of a book.
fl uticasone propionate/ azelastine hydrochloride


A next step in nasal and ocular symptom control


For moderate/severe seasonal and perennial allergic rhinitis


2


Indications: Dymista is indicated for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered suffi cient.2


Dymista® Nasal Spray, suspension. Prescribing Information.


Presentation: Nasal spray suspension. Each gram of suspension contains 1000 micrograms of azelastine hydrochloride and 365 micrograms of fl uticasone propionate. Indications: Relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if treatment with intranasal antihistamine or glucocorticoid alone is not considered suffi cient. Dosage and administration: Adults and adolescents (12 years and older): One actuation into each nostril twice daily. Children below 12 years: not recommended as safety and effi cacy has not been established in this age group. Contra-indications: Hypersensitivity to azelastine hydrochloride or fl uticasone propionate or any of the other ingredients in this medicine. Warnings and precautions: Avoid concomitant use with ritonavir. Systemic effects of nasal corticosteroids may occur. Systemic exposure in severe liver disease may be increased. Dymista®


may result in clinically signifi cant


adrenal suppression. Monitor patients who experience changes in vision or have a history of ocular pressure,


glaucoma and/or cataract. If adrenal function is impaired, take care when changing medication to Dymista®


. In patients with infections, recent surgery or injury to nose or mouth, weigh benefi ts against risks of use. Contains benzalkonium hydrochloride. Experience of use in pregnancy and lactation is limited. Dymista®


only be used if the potential benefi t justifi es the potential risk. Dymista®


has minor infl uence on ability to drive and


use machines. Undesirable Effects: Epistaxis, headache, dysgeusia, unpleasant smell, hypersensitivity reactions including anaphylactic reactions, angioedema, bronchospasm, glaucoma, increased intraocular pressure, cataract, septal perforation, growth retardation may be possible in adolescents receiving prolonged treatment and growth should be monitored regularly. Consult the Summary of Product Characteristics for other side effects. Package Quantities and Basic Price (UK): £14.80 for 23g bottle. Each spray (0.14 g) contains 137 mcg of azelastine hydrochloride and 50 mcg of fl uticasone propionate. Legal category: POM. Product Licence Holder: Meda Pharmaceuticals Ltd, Skyway House, Parsonage Road,


Takeley, Bishops Stortford CM22 6PU. Tel 0845 460 0000. Marketing Authorisation Number: PL 15142/0258. Date of preparation: December 2014. UK/DYM/14/0015(1).


should


Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Meda Pharmaceuticals Ltd.


References: 1. Meltzer E et al. Int Arch Allergy Immunol 2013; 161:369-377.


2. Dymista® Summary of Product Characteristics.


UK/DYM/16/0001a Date of preparation: January 2016


1,2





D


A


E


C


C


E


P


T


B


Y





B


A


C


E


C


E


P


T


D


Y


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108